Skip to main content
Figure 5 | Journal of Translational Medicine

Figure 5

From: Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: How markers of β-cell loss may assist

Figure 5

Suggested biomarker progression during disease development and future segregation of T2DM patients. A) Proposed biomarker development during T2DM initiation and progression. 1) Β-cell specific degradation markers, 2) Fasting plasma glucose (FPG), 3) HbA1c and other early glycation products, 4) Advanced glycation end-products (AGEs). B) Diagnosis of T2DM is based on an elevated concentration of HbA1c. Diagnosed T2DM patients can currently be offered all types of T2DM treatments. Future segregation of T2DM patients based on β-cell mass, could direct sub-groups of patients to more specific types of treatments.

Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us